{"name":"Mundipharma Research Limited","slug":"mundipharma-research-limited","ticker":"","exchange":"","domain":"","description":"","hq":"Limburg an der Lahn","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"Flixotide pMDI 250 micrograms","genericName":"Flixotide pMDI 250 micrograms","slug":"flixotide-pmdi-250-micrograms","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Flutiform 250/10 micrograms","genericName":"Flutiform 250/10 micrograms","slug":"flutiform-250-10-micrograms","indication":"Asthma maintenance therapy in patients requiring combination inhaled corticosteroid and long-acting beta-2 agonist","status":"phase_3"},{"name":"Flixotide plus Foradil","genericName":"Flixotide plus Foradil","slug":"flixotide-plus-foradil","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Fluticasone/formoterol BAI","genericName":"Fluticasone/formoterol BAI","slug":"fluticasone-formoterol-bai","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Flutiform 50/5 micrograms","genericName":"Flutiform 50/5 micrograms","slug":"flutiform-50-5-micrograms","indication":"Asthma maintenance therapy in adults and adolescents","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Rezafungin for Injection","genericName":"Rezafungin for Injection","slug":"rezafungin-for-injection","indication":"Invasive candidiasis","status":"phase_3"},{"name":"BTDS","genericName":"BTDS","slug":"btds","indication":"Other","status":"phase_2"},{"name":"Flutiform","genericName":"Flutiform","slug":"flutiform","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Flixotide","genericName":"Flixotide","slug":"flixotide","indication":"Allergic asthma","status":"marketed"}]}],"pipeline":[{"name":"Rezafungin for Injection","genericName":"Rezafungin for Injection","slug":"rezafungin-for-injection","phase":"phase_3","mechanism":"Rezafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase.","indications":["Invasive candidiasis","Candidemia"],"catalyst":""},{"name":"BTDS","genericName":"BTDS","slug":"btds","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Flixotide","genericName":"Flixotide","slug":"flixotide","phase":"marketed","mechanism":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","indications":["Allergic asthma","Allergic rhinitis","Asthma management","Atopic dermatitis","Bronchospasm Prevention with COPD"],"catalyst":""},{"name":"Flixotide pMDI 250 micrograms","genericName":"Flixotide pMDI 250 micrograms","slug":"flixotide-pmdi-250-micrograms","phase":"phase_3","mechanism":"Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Flutiform","genericName":"Flutiform","slug":"flutiform","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Flutiform 250/10 micrograms","genericName":"Flutiform 250/10 micrograms","slug":"flutiform-250-10-micrograms","phase":"phase_3","mechanism":"Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma.","indications":["Asthma maintenance therapy in patients requiring combination inhaled corticosteroid and long-acting beta-2 agonist"],"catalyst":""},{"name":"Flixotide plus Foradil","genericName":"Flixotide plus Foradil","slug":"flixotide-plus-foradil","phase":"phase_3","mechanism":"Flixotide plus Foradil is a combination inhaler that delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Fluticasone/formoterol BAI","genericName":"Fluticasone/formoterol BAI","slug":"fluticasone-formoterol-bai","phase":"phase_3","mechanism":"Fluticasone/formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Flutiform 50/5 micrograms","genericName":"Flutiform 50/5 micrograms","slug":"flutiform-50-5-micrograms","phase":"phase_3","mechanism":"Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma.","indications":["Asthma maintenance therapy in adults and adolescents"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE13d0Y1OGNyZUdSMVUwVktfRkliOER6SzVVM3lQbXlGM3dPVWhUc3JMZ3ZabzJaZXNsVjNVRnlZVXpzSVgta2dkSGhOSjRESTIwYTB4OWoyUjN2TTg?oc=5","date":"2026-02-26","type":"pipeline","source":"Britannica","summary":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma - Britannica","headline":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNZ3BTWVVLVHg0eF9nZUx5VFk4VnZaNFZ6Z3VOQ3FwUThmN016MlhKZ2RpSHFnOVBfN254ZUNlUDFLTWpXUWpfN2FPWWF5X1dTOGVXdnA0Y3F3Z2RXWTI4b1dyZmZzT0owa01wY0RsZ2MzMDdqYlMtNnRZU2RMRjQxMHd5Sm9oSnBKSmlkSGxmcHdCVHFZR3JnSEFmZHI?oc=5","date":"2025-10-10","type":"trial","source":"Yahoo Finance","summary":"Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin) - Yahoo Finance","headline":"Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPRVd6WXpfckdJZGoxTUJaOGRyaXpqcXgzX1RSS0xmRFp6MEx5NUJqQkZfaW5rQTRSMDBJWG9mZ2ZnQUMtZl9WTkhoNFdiZ1hyekYxUXczTzhhZlZtd1ZsSWg0d2plTnZPU3pUY0xsR0g0MnQ2OGUtcXdzOExuaEhJdDNoMGRLZ0owUzZ0WHFweHZRZnlrODBud0htTzUwcndEb1A2QzdQb3dOTFBMSGM3MmJCZEVmZmthNmdibmN6MnBNYmtFLTdNSzl3X2FZSmUyN3lNemFaQ1JmNnI2dU9ZLWVMSFgyQXlzU0thSGl3ZWpDbklKbjlpelA4WEFhQTlxMzIyYlB3cHRGNWhDRnVmb0Z0NlVOSnFSU3B0Zzh0eFgtbWlGTEtlMURhNjFUd3dFMEow?oc=5","date":"2025-07-21","type":"pipeline","source":"GlobeNewswire","summary":"Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire","headline":"Cutaneous T-cell Lymphoma Market Anticipates Impressive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNTWo1M0NMT1pzY1pDcjN1SGJrTmZmcE8xWTZGMVlEUTlSUDU4TzVFUUNUSmx1WjNSRGQ5VWh5VGhQRERlLU5qWnlRRF9GVzkydUpkMldUOTFfZ1B2S0dtLXpfSVZUQmhjeDRWVE01c2pPMjlKVjRRNzJtR21FV1RhbmZTTjkwV05JVDg2VnhZamFlZVM3T3hKOEFnQ2dLTXc?oc=5","date":"2024-09-17","type":"earnings","source":"Finance Uncovered","summary":"Revealed: How the Sackler family’s opioid empire continues to make hundreds of millions of dollars in profits around the world - Finance Uncovered","headline":"Revealed: How the Sackler family’s opioid empire continues to make hundreds of millions of dollars in profits around the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVVVmOXZ3akk4TnRJeUxxejF0cFBQNXp6cGJYX0M4ZlBONGZKaGxUeW9UT0pOSjFnc3R5SzhpNHpZaks1dHhvSnBSQWdlSWhhY0pWUTZ3VTdEenFESFFxLWR4eFhSMi1FTEZXOV9nQTZiLXNsR2EwR2RFbW1tUWMwX2NYdlZ0SGlmWUh2MVR3c2UxY0YyZHAtd0dNQXhveXRlUzB3YndOdGRZRU42RlZrVzBQQ1pyYUhLUzZR?oc=5","date":"2024-09-17","type":"pipeline","source":"The Examination","summary":"In the US, opioid-maker Purdue is bankrupt. Its global counterparts make millions. - The Examination","headline":"In the US, opioid-maker Purdue is bankrupt. Its global counterparts make millions.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOWUhMX2hkSncyZ1J3Q0JwQ1FwQ2pHZWhVOXdQSXl0V3hqMW5PZzIzWWsxX2F6bmlKTHVGVGQ2UmNLMWN6Wlg4T1ZnaDlqZHZIUW4tVzN6blRiemIyX3dyMkRRdzlJUzhPUnBvamVXUXZ3dHpxbGlMd1AxaEJvTWFxbnlrRzZleXZpYTk0aWZyM1g?oc=5","date":"2024-02-14","type":"regulatory","source":"Frontiers","summary":"Neuropsychiatric Symptoms and Their Association With Sex, Age, and Enzyme Replacement Therapy in Fabry Disease: A Systematic Review - Frontiers","headline":"Neuropsychiatric Symptoms and Their Association With Sex, Age, and Enzyme Replacement Therapy in Fabry Disease: A System","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE15Tjc4MmsteklCTkJLejhuYmk2VlZyS3d2eGdLbDlYcF9wTWx3UzdxNndlV0owNFhlbjlQV1lVcFZtb3dlOVlDcUJKcjNfRU1oRTloaGxRSGNpWkNBRXBwWEd1X1NfaWhL?oc=5","date":"2023-09-25","type":"trial","source":"Wiley Online Library","summary":"Subgrouping of facilitatory or inhibitory conditioned pain modulation responses in patients with chronic knee pain. Explorative analysis from a multicentre trial - Wiley Online Library","headline":"Subgrouping of facilitatory or inhibitory conditioned pain modulation responses in patients with chronic knee pain. Expl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOS2NDYl9nRUZuY0tCVnI4NE9uNHVkZUltaDlPQktMN1FMdEQtcjRUVXQ1dW1KakRlbU1FTEppVmFZekVzRThfZ0R0bnFSQjAwT1dXeElIaGlMWTM0REhZUk9EUXRPd25xdEZ1Vl9xNHNaM1ZPcnV4VThMQk92bFo1ODB6V05fQjk0RU5NaGVaanpXSkN5dHAyaTFJNEhfT3ZoYlZHbHlWN2JlX1hoeDR3UmJMU0c?oc=5","date":"2023-08-01","type":"deal","source":"Nasdaq","summary":"Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals ","headline":"Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE8teWZ5TEdBdm14SmpxQ3pwYmUxM3A4R29ZRjNUOXJSeTdfT1pMNzdxLUozV3dscUwxMXNUU0J1T256bmVjQWdnSTRrV21COU0zTHBmSDVvVGhINFE4VjAtQ1hpTlR3WkZWRHpuS0xR0gFyQVVfeXFMTmQ0Z3FVT1Z4bGVDZi01R1VYeHhhaVJHTS1FTzRTdHBObVNkY0l0S3o4SHdaWDdudEFwUmpkNS1FSWhPYWVXdDhMYUxkaml4ZUpfMGNIWEF6TENNZGxKM29iWnBWR1hNMFZESVQ5STFvUS1R?oc=5","date":"2023-01-03","type":"pipeline","source":"koreabiomed.com","summary":"Are results of Mundipharma's 25-year business in Korea debt of ₩200 billion? - koreabiomed.com","headline":"Are results of Mundipharma's 25-year business in Korea debt of ₩200 billion?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNYzZCdHpiZjhOMmY3Um9Gbzl4TS1rZ0FVdHdiSnhQOGt2UzZJNm55SGVJWXR3TzB6anRlSWhBaGxBWldybFNNUklNZXF0T3ZKUDRLclFCbllSTkwxNVpOQ2hpQU1HWFh2cFhpdlRVZkVKbFdtaUtOMUNSOXlFWVNrdUJUajlQdlVFbjN1WThHR1VpNHNlMVFTeWVseXR3OEFsNFFEdHBuN09PdWZ5LUFuOHF6cw?oc=5","date":"2019-03-30","type":"earnings","source":"Bloomberg.com","summary":"OxyContin Billionaires Chase Global Profits to Offset U.S. Woes - Bloomberg.com","headline":"OxyContin Billionaires Chase Global Profits to Offset U.S. Woes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQVW5IZmhuOFVMVmllQVYxaV9zbXdPejZlbnZaWUYyX0JMQVZjNTV1Wk4zWWxiZzJnLXhhT2JpeTVuY0d6czhOcXk3UVViQzh3b1FwWEpzb3pYSkllM0NpZlQ2VHhGeDdzS3NNY3VRY3ZXNkloQTlSaXNkckNqdTRkNGlRUGNWdWxPUVRwRjlZWXlhSFpCU2RfNkVHLWg?oc=5","date":"2018-03-20","type":"deal","source":"BioPharma Dive","summary":"Mundipharma inks third biosimilar deal with Celltrion - BioPharma Dive","headline":"Mundipharma inks third biosimilar deal with Celltrion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxPSVFJZjFSTkYxSW5JejVPTTNXbzFvVlhzaDZ5N0gxaUdxZ2prRFlxbTQ4Z0hzN1JCcGcwX2hEWjdycjFGMG9KYXIxMF9ERms4blVJQURvMmlUNzYxcTlyMkF1TDRlVkJZSTcyT0J4OTRmeTZiUm0yWF85dFhmMjVpLW8xQ0lSdHl1NTJsem92dG9USWJiMzkwUGVxY2NiV1k5bFJWbzlBWWJTd19WVmVFcThDSHlEc1hXSjFFYVU5TWZxb3RoX0VDU29EeE1iMXNxQ0JFcW5oR1BHd3psR2l2YXpiSzZ6elA4ME9Mc2FINDVwTWlYZTkzNU9aQzF0QlFhVW5VcERRM3IxTkNUdmIwRVZQWUpCT1BUSVE?oc=5","date":"2016-05-15","type":"deal","source":"PR Newswire","summary":"Mundipharma and Purdue Pharma Expand Pain Pipeline with New Deal for First-in-Class Sigma-1 Antagonist (S1A or MR309/E-52862) from ESTEVE - PR Newswire","headline":"Mundipharma and Purdue Pharma Expand Pain Pipeline with New Deal for First-in-Class Sigma-1 Antagonist (S1A or MR309/E-5","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":7,"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}